Details for New Drug Application (NDA): 086986
✉ Email this page to a colleague
NDA 086986 describes LANORINAL, which is a drug marketed by Sandoz and Lannett and is included in two NDAs. It is available from three suppliers. Additional details are available on the LANORINAL profile page.
The generic ingredient in LANORINAL is aspirin; butalbital; caffeine. There are twenty-two drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the aspirin; butalbital; caffeine profile page.
The generic ingredient in LANORINAL is aspirin; butalbital; caffeine. There are twenty-two drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the aspirin; butalbital; caffeine profile page.
Summary for 086986
| Tradename: | LANORINAL |
| Applicant: | Lannett |
| Ingredient: | aspirin; butalbital; caffeine |
| Patents: | 0 |
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 325MG;50MG;40MG | ||||
| Approval Date: | Oct 18, 1985 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
